IPO & Public Markets

AI agent developer Vida Global Inc. completes its IPO, but a volatile stock debut raises questions about its future in a booming but competitive industry.

With backing from Eli Lilly, Cabaletta Bio's $150M financing will accelerate its potentially curative cell therapies for autoimmune diseases.

LifeSci Advisors' hire of finance and IR veteran Matthew Osborne signals a strategic push amid a competitive market and a rebounding biotech IPO landscape.

The struggling footwear brand is selling its assets to become NewBird AI, a GPU provider. Is it a visionary gamble or a desperate move in the AI gold rush?

In a major strategic move, Premier Research appoints Paul Spreen as CCO, signaling a bold push to capture the rebounding biotech market.

Avory & Co. enters the crowded ETF market with AVRY, an actively managed fund shunning trends for a concentrated portfolio of high-quality stocks.

Nearly a century old, NPF Investment Advisors launches an actively managed ETF, aiming to deliver tax efficiency and long-term growth to a new generation.

As stablecoin rules tighten, a new partnership between Circle and CyberScope signals a major shift towards institutional-grade security in Web3.

As Moelis & Co. prepares to report its 2025 results, investors are watching to see if the firm capitalized on a record year for dealmaking.

As Uxin prepares to report Q3 results, all eyes are on its ambitious superstore strategy and whether it can drive profitability in a complex market.